Many elderly people have high blood pressure themselves, but refuse to stick to their antihypertensive medication, thinking that taking it for a long time will have many side effects.
Data from a study presented at the annual meeting of the European Society of Medical Oncology in 2022 showed that lenvatinib in combination with Pembrolizumab could give 100% efficacy in this group of patients.
